FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313233105> ?p ?o ?g. }

• W4313233105 endingPage "40" @default.
• W4313233105 startingPage "39" @default.
• W4313233105 abstract "Introduction: Acute Kidney Injury is commonly present in Covid-19 hospitalised patients whereas chronic kidney disease and end-stage renal disease are also common comorbidities in patients who develop severe COVID-19. These patients require antiviral medication as early as possible but there is no current guidelines for use of Remdesivir therapy in these patents and drug is not used initially in these patients. Antiviral strategies are desperately needed in this population to treat these patients as early as possible. Material And Methods: We conducted an observational, retrospective cohort study of adults with COVID-19 conrmed by RT-PCR who had eGFR < 30mL/min/1.73m2 or received RRT prior to receiving at least one dose of Remdesivir. eGFR was estimated from the serum creatinine value just prior to the rst dose of Remdesivir using the Chronic Kidney Disease Epidemiology Collaboration calculator. The majority of patients requiring supplemental oxygen were offered Remdesivir; eGFR cut-offs were not used as a strict exclusion criteria. All patients with eGFR < 30mL/min/1.73m2 who received at least one dose of Remdesivir in hospital were included in the study. AKI was dened as at least a 1.5- fold rise in creatinine from baseline per KDIGO criteria. CKD was dened as eGFR < 60mL/min/1.73m2 between 7-365 days prior to admission. Patients with “stable CKD” did not meet criteria for AKI at the time of starting Remdesivir. ESRD was dened as requiring RRT > 3 months prior to hospitalization. The primary objectives were to describe changes in ALT, AST, and Bilirubin and serum creatinine during Remdesivir therapy, and to report adverse effects attributed to Remdesivir. A Results: total of 41 patients with eGFR <30 ml/min per 1.73 m2 at the time of Remdesivir initiation were included in the study. 27 patients were in intensive care, and 14 patients were mechanically ventilated at the time of Remdesivir initiation. At the time of Remdesivir initiation, 30 patients were receiving RRT. 11 patients with eGFR <30 ml/min per 1.73 m2 were not on RRT at the time of starting Remdesivir. Four patients developed ALT more than the upper limit of normal and only two patients developed ALT more than 5 times, that may be contributory to other factor also. In general, limited information is available Conclusion: on the impact of SARS-CoV-2 infection in patients with eGFR less than 30. Impact of Remdesivir on these patients and their liver and kidney functions are not well studied. Although the available clinical data are limited, but it shows that impact of Remdesivir on liver and kidney function in patients of eGFR less than 30 is limited. However further studies are needed." @default.
• W4313233105 created "2023-01-06" @default.
• W4313233105 creator A5029507278 @default.
• W4313233105 creator A5034727400 @default.
• W4313233105 creator A5062401953 @default.
• W4313233105 date "2022-12-01" @default.
• W4313233105 modified "2023-09-30" @default.
• W4313233105 title "REMDESIVIR IN PATIENTS WITH ACUTE OR CHRONIC KIDNEY DISEASE IN COVID-19 AND IMPACT ON LIVER AND KIDNEY FUNCTION" @default.
• W4313233105 cites W3011516015 @default.
• W4313233105 cites W3032677067 @default.
• W4313233105 cites W3040751560 @default.
• W4313233105 cites W3045952783 @default.
• W4313233105 cites W3135015887 @default.
• W4313233105 cites W3165656738 @default.
• W4313233105 doi "https://doi.org/10.36106/ijar/6101458" @default.
• W4313233105 hasPublicationYear "2022" @default.
• W4313233105 type Work @default.
• W4313233105 citedByCount "0" @default.
• W4313233105 crossrefType "journal-article" @default.
• W4313233105 hasAuthorship W4313233105A5029507278 @default.
• W4313233105 hasAuthorship W4313233105A5034727400 @default.
• W4313233105 hasAuthorship W4313233105A5062401953 @default.
• W4313233105 hasConcept C126322002 @default.
• W4313233105 hasConcept C159641895 @default.
• W4313233105 hasConcept C167135981 @default.
• W4313233105 hasConcept C177713679 @default.
• W4313233105 hasConcept C2778653478 @default.
• W4313233105 hasConcept C2779541074 @default.
• W4313233105 hasConcept C2780306776 @default.
• W4313233105 hasConcept C2780472472 @default.
• W4313233105 hasConcept C2908647359 @default.
• W4313233105 hasConcept C71924100 @default.
• W4313233105 hasConcept C99454951 @default.
• W4313233105 hasConceptScore W4313233105C126322002 @default.
• W4313233105 hasConceptScore W4313233105C159641895 @default.
• W4313233105 hasConceptScore W4313233105C167135981 @default.
• W4313233105 hasConceptScore W4313233105C177713679 @default.
• W4313233105 hasConceptScore W4313233105C2778653478 @default.
• W4313233105 hasConceptScore W4313233105C2779541074 @default.
• W4313233105 hasConceptScore W4313233105C2780306776 @default.
• W4313233105 hasConceptScore W4313233105C2780472472 @default.
• W4313233105 hasConceptScore W4313233105C2908647359 @default.
• W4313233105 hasConceptScore W4313233105C71924100 @default.
• W4313233105 hasConceptScore W4313233105C99454951 @default.
• W4313233105 hasLocation W43132331051 @default.
• W4313233105 hasOpenAccess W4313233105 @default.
• W4313233105 hasPrimaryLocation W43132331051 @default.
• W4313233105 hasRelatedWork W2063356426 @default.
• W4313233105 hasRelatedWork W2143569590 @default.
• W4313233105 hasRelatedWork W2148063732 @default.
• W4313233105 hasRelatedWork W2341805355 @default.
• W4313233105 hasRelatedWork W2516528078 @default.
• W4313233105 hasRelatedWork W2945484301 @default.
• W4313233105 hasRelatedWork W3120579756 @default.
• W4313233105 hasRelatedWork W3123050808 @default.
• W4313233105 hasRelatedWork W3154893655 @default.
• W4313233105 hasRelatedWork W4310216711 @default.
• W4313233105 isParatext "false" @default.
• W4313233105 isRetracted "false" @default.
• W4313233105 workType "article" @default.